The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis

Charles P. Andrews, Paul H. Ratner, Benjamin R. Ehler, Edward G. Brooks, Bradley H Pollock, Dan A. Ramirez, Robert L. Jacobs

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Clinical trials of seasonal allergic rhinoconjunctivitis use the mountain cedar (Juniperus ashei) season as the predominate model. Objective: To evaluate clinical trials of rhinoconjunctivitis using mountain cedar, to present analysis of pollen counts during 18 seasons, and to discuss the model. Methods: The medical literature was searched for clinical trials performed using mountain cedar either in or out of season. Pollen counts were recorded and analyzed for the duration of 18 seasons. Results: Thirty-eight trials were identified. Of these, 1 evaluated onset of allergy, 8 were immunotherapy trials, 28 were pharmaceutical clinical trials, and 1 studied symptoms elicited in a pollen challenge chamber trial. Many generic equivalency trials are unreported. In the 18 years of counts in the Texas Hill Country, a dependable and intense pollen density was present in every season. The combination of dependable seasons without confounding pollens, the large number of allergic patients, and the ability to concentrate resources in one geographic area has made mountain cedar allergy a mainstay for therapeutic trials for allergic rhinoconjunctivitis. Conclusion: Mountain cedar allergy presents a dependable and durable model of allergic rhinoconjunctivitis.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalAnnals of Allergy, Asthma and Immunology
Volume111
Issue number1
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Pollen
Clinical Trials
Hypersensitivity
Juniperus
Therapeutic Equivalency
Immunotherapy
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis. / Andrews, Charles P.; Ratner, Paul H.; Ehler, Benjamin R.; Brooks, Edward G.; Pollock, Bradley H; Ramirez, Dan A.; Jacobs, Robert L.

In: Annals of Allergy, Asthma and Immunology, Vol. 111, No. 1, 07.2013, p. 9-13.

Research output: Contribution to journalArticle

Andrews, Charles P. ; Ratner, Paul H. ; Ehler, Benjamin R. ; Brooks, Edward G. ; Pollock, Bradley H ; Ramirez, Dan A. ; Jacobs, Robert L. / The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis. In: Annals of Allergy, Asthma and Immunology. 2013 ; Vol. 111, No. 1. pp. 9-13.
@article{39a6b2faf39f467d8de14ac6031338d2,
title = "The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis",
abstract = "Background: Clinical trials of seasonal allergic rhinoconjunctivitis use the mountain cedar (Juniperus ashei) season as the predominate model. Objective: To evaluate clinical trials of rhinoconjunctivitis using mountain cedar, to present analysis of pollen counts during 18 seasons, and to discuss the model. Methods: The medical literature was searched for clinical trials performed using mountain cedar either in or out of season. Pollen counts were recorded and analyzed for the duration of 18 seasons. Results: Thirty-eight trials were identified. Of these, 1 evaluated onset of allergy, 8 were immunotherapy trials, 28 were pharmaceutical clinical trials, and 1 studied symptoms elicited in a pollen challenge chamber trial. Many generic equivalency trials are unreported. In the 18 years of counts in the Texas Hill Country, a dependable and intense pollen density was present in every season. The combination of dependable seasons without confounding pollens, the large number of allergic patients, and the ability to concentrate resources in one geographic area has made mountain cedar allergy a mainstay for therapeutic trials for allergic rhinoconjunctivitis. Conclusion: Mountain cedar allergy presents a dependable and durable model of allergic rhinoconjunctivitis.",
author = "Andrews, {Charles P.} and Ratner, {Paul H.} and Ehler, {Benjamin R.} and Brooks, {Edward G.} and Pollock, {Bradley H} and Ramirez, {Dan A.} and Jacobs, {Robert L.}",
year = "2013",
month = "7",
doi = "10.1016/j.anai.2013.05.004",
language = "English (US)",
volume = "111",
pages = "9--13",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "1",

}

TY - JOUR

T1 - The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis

AU - Andrews, Charles P.

AU - Ratner, Paul H.

AU - Ehler, Benjamin R.

AU - Brooks, Edward G.

AU - Pollock, Bradley H

AU - Ramirez, Dan A.

AU - Jacobs, Robert L.

PY - 2013/7

Y1 - 2013/7

N2 - Background: Clinical trials of seasonal allergic rhinoconjunctivitis use the mountain cedar (Juniperus ashei) season as the predominate model. Objective: To evaluate clinical trials of rhinoconjunctivitis using mountain cedar, to present analysis of pollen counts during 18 seasons, and to discuss the model. Methods: The medical literature was searched for clinical trials performed using mountain cedar either in or out of season. Pollen counts were recorded and analyzed for the duration of 18 seasons. Results: Thirty-eight trials were identified. Of these, 1 evaluated onset of allergy, 8 were immunotherapy trials, 28 were pharmaceutical clinical trials, and 1 studied symptoms elicited in a pollen challenge chamber trial. Many generic equivalency trials are unreported. In the 18 years of counts in the Texas Hill Country, a dependable and intense pollen density was present in every season. The combination of dependable seasons without confounding pollens, the large number of allergic patients, and the ability to concentrate resources in one geographic area has made mountain cedar allergy a mainstay for therapeutic trials for allergic rhinoconjunctivitis. Conclusion: Mountain cedar allergy presents a dependable and durable model of allergic rhinoconjunctivitis.

AB - Background: Clinical trials of seasonal allergic rhinoconjunctivitis use the mountain cedar (Juniperus ashei) season as the predominate model. Objective: To evaluate clinical trials of rhinoconjunctivitis using mountain cedar, to present analysis of pollen counts during 18 seasons, and to discuss the model. Methods: The medical literature was searched for clinical trials performed using mountain cedar either in or out of season. Pollen counts were recorded and analyzed for the duration of 18 seasons. Results: Thirty-eight trials were identified. Of these, 1 evaluated onset of allergy, 8 were immunotherapy trials, 28 were pharmaceutical clinical trials, and 1 studied symptoms elicited in a pollen challenge chamber trial. Many generic equivalency trials are unreported. In the 18 years of counts in the Texas Hill Country, a dependable and intense pollen density was present in every season. The combination of dependable seasons without confounding pollens, the large number of allergic patients, and the ability to concentrate resources in one geographic area has made mountain cedar allergy a mainstay for therapeutic trials for allergic rhinoconjunctivitis. Conclusion: Mountain cedar allergy presents a dependable and durable model of allergic rhinoconjunctivitis.

UR - http://www.scopus.com/inward/record.url?scp=84879553232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879553232&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2013.05.004

DO - 10.1016/j.anai.2013.05.004

M3 - Article

C2 - 23806453

AN - SCOPUS:84879553232

VL - 111

SP - 9

EP - 13

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 1

ER -